Steven C Campbell1, Peter E Clark2, Sam S Chang3, Jose A Karam4, Lesley Souter5, Robert G Uzzo6. 1. Cleveland Clinic, Cleveland, Ohio. 2. Atrium Health Levine Cancer Institute, Charlotte, North Carolina. 3. Vanderbilt University Medical Center, Nashville, Tennessee. 4. MD Anderson Cancer Center, Houston, Texas. 5. Consultant Methodologist, Ontario, Canada. 6. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Abstract
PURPOSE: This AUA Guideline focuses on evaluation/counseling/management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS/ METHODS: The Renal Mass and Localized Renal Cancer guideline underwent an update literature review which resulted in the 2021 amendment. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (table 1). RESULTS: Great progress has been made regarding the evaluation/management of clinically-localized renal masses. These guidelines provide updated, evidence-based recommendations regarding evaluation/counseling including the evolving role of renal-mass-biopsy (RMB). Given great variability of clinical/oncologic/functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Options for intervention (partial-nephrectomy (PN), radical-nephrectomy (RN), and thermal-ablation (TA)) are reviewed including recent data about comparative-effectiveness/potential morbidities. Oncologic issues are prioritized while recognizing the importance of functional-outcomes for survivorship. Granular criteria for RN are provided to help reduce overutilization of RN while also avoiding imprudent PN. Priority for PN is recommended for clinical T1a lesions, along with selective utilization of TA, which has good efficacy for tumors≤3.0 cm. Recommendations for genetic-counseling have been revised and considerations for adjuvant-therapies are addressed. Active-surveillance and follow-up after intervention are discussed in an adjunctive article. CONCLUSION: Several factors require consideration during counseling/management of patients with clinically-localized renal masses including general health/comorbidities, oncologic-considerations, functional-consequences, and relative efficacy/potential morbidities of various management-strategies.
PURPOSE: This AUA Guideline focuses on evaluation/counseling/management of adult patients with clinically-localized renal masses suspicious for cancer, including solid-enhancing tumors and Bosniak 3/4 complex-cystic lesions. MATERIALS/ METHODS: The Renal Mass and Localized Renal Cancer guideline underwent an update literature review which resulted in the 2021 amendment. When sufficient evidence existed, the body of evidence was assigned a strength rating of A (high), B (moderate), or C (low) for support of Strong, Moderate, or Conditional Recommendations. In the absence of sufficient evidence, additional information is provided as Clinical Principles and Expert Opinions (table 1). RESULTS: Great progress has been made regarding the evaluation/management of clinically-localized renal masses. These guidelines provide updated, evidence-based recommendations regarding evaluation/counseling including the evolving role of renal-mass-biopsy (RMB). Given great variability of clinical/oncologic/functional characteristics, index patients are not utilized and the panel advocates individualized counseling/management. Options for intervention (partial-nephrectomy (PN), radical-nephrectomy (RN), and thermal-ablation (TA)) are reviewed including recent data about comparative-effectiveness/potential morbidities. Oncologic issues are prioritized while recognizing the importance of functional-outcomes for survivorship. Granular criteria for RN are provided to help reduce overutilization of RN while also avoiding imprudent PN. Priority for PN is recommended for clinical T1a lesions, along with selective utilization of TA, which has good efficacy for tumors≤3.0 cm. Recommendations for genetic-counseling have been revised and considerations for adjuvant-therapies are addressed. Active-surveillance and follow-up after intervention are discussed in an adjunctive article. CONCLUSION: Several factors require consideration during counseling/management of patients with clinically-localized renal masses including general health/comorbidities, oncologic-considerations, functional-consequences, and relative efficacy/potential morbidities of various management-strategies.
Authors: Nityam Rathi; Yosuke Yasuda; Worapat Attawettayanon; Diego A Palacios; Yunlin Ye; Jianbo Li; Christopher Weight; Mohammed Eltemamy; Tarik Benidir; Robert Abouassaly; Steven C Campbell Journal: Int Urol Nephrol Date: 2022-07-17 Impact factor: 2.266
Authors: Nityam Rathi; Yosuke Yasuda; Diego Aguilar Palacios; Worapat Attawettayanon; Jianbo Li; Bimal Bhindi; R Houston Thompson; Michael A Liss; Ithaar H Derweesh; Christopher J Weight; Mohammed Eltemamy; Robert Abouassaly; Steven C Campbell Journal: Eur Urol Open Sci Date: 2022-05-05
Authors: Jasmin Runtemund; Johannes Rübenthaler; Niklas von Münchhausen; Maria Ingenerf; Freba Grawe; Gloria Biechele; Felix Gerhard Gassert; Fabian Tollens; Johann Rink; Sasa Cecatka; Christine Schmid-Tannwald; Matthias F Froelich; Dirk-André Clevert; Moritz L Schnitzer Journal: Cancers (Basel) Date: 2022-04-29 Impact factor: 6.575
Authors: Selma Masic; Marshall Strother; Laura C Kidd; Brian Egleston; Avery Braun; Abhishek Srivastava; Marc Smaldone; Barton Milestone; Rosaleen Parsons; Rosalia Viterbo; Richard Greenberg; David Chen; Alexander Kutikov; Robert Uzzo Journal: Urology Date: 2021-08-08 Impact factor: 2.633